Ka Manaʻo Kūkākūkā e pili ana i ka hoʻohana ʻana i ka lāʻau lapaʻau o ka waika PDRN i ka Dermatology 

I nā makahiki i hala iho nei, ua loaʻa ka polydeoxyribonucleic acid (PDRN) i ka nānā ākea a me ka hoʻohana ʻana i ke kahua o ka dermatology, akā aia nō ka nele o ka ʻike lokahi e pili ana i ka standardization o kāna noi. Ua hoʻopuka pū ka Laser Cosmetology Group o ka Chinese Medical Association's Branch of Aesthetic and Plastic Surgeons a me ka Medical Cosmetology Group o ka Chinese Association of Integrative Medicine i ka "Expert Consensus on the Clinical Application of Polydeoxyribonucleic Acid in Dermatology," e manaʻo ana e hāʻawi i nā kauka i nā ʻōlelo aʻoaʻo ʻepekema a me ka pahuhopu e alakaʻi iā lākou i ka hoʻohana pono ʻana o ka PDRN i ka hoʻomaʻamaʻa pono ʻana.

ʻO Pharmacokinetics a me Mechanism of Action of PDRN

Aia ka PDRN i loko o ka plasma ma ke ʻano manuahi a ʻaʻole pili i nā apolipoproteins plasma. Hoʻopili maikaʻi ʻia kona puʻunaue me ke kahe o ke koko. ʻAʻole hoʻololi ʻia kēia lāʻau e ke ake; ua hoʻohaʻahaʻa nui ʻia e nā nucleases DNA plasma non-specific a i ʻole nā ​​​​nucleases membrane cell e hana i ka mea hana, mononucleotide. ʻO ka mea hope loa, hoʻokuʻu ʻia ka hapa nui o ia mea i loko o ka mimi (ma kahi o 65%), me kahi liʻiliʻi i hoʻokuʻu ʻia i loko o nā feces.

Hoʻopuka ka PDRN degradation i nā nucleotides a me nā nucleosides, e hāʻawi ana i nā mea maka no ka hoʻoponopono ʻana i ka pōʻino DNA a me ka hoʻoikaika wikiwiki ʻana i ka hoʻoponopono ʻana i ka DNA cell i pōʻino a me ka hoʻonui ʻana o nā cell.

Hoʻohana maʻi o PDRN ma Dermatology

1. Hoola Eha

Ua ʻike ʻia ka noiʻi o kēia manawa ua komo ʻo PDRN i ke kaʻina hana ho'ōla ʻeha mai nā kihi he nui, me ka pale ʻana i nā pane inflammatory nui, ka wikiwiki o ka epidermal a me ka dermal renewal, ka hoʻoulu ʻana i ka collagen deposition, a me ka upregulating angiogenesis a me nā mea hoʻoponopono ʻē aʻe e like me VEGF. I nā poʻe maʻi graft ʻili autologous, intramuscular, subcutaneous, a i ʻole topical PDRN injections ma ka wahi ʻeha hiki ke hoʻolalelale i ka re-epithelialization a me ka manawa ho'ōla. Eia kekahi, hiki i ka noi PDRN ma hope o ka ho'ōla laser fractional CO2 ke hoʻolalelale i ka ho'ōla ʻana i ka ʻeha; no laila, hiki ke noʻonoʻo ʻia ka PDRN ma hope o ka hoʻomaʻamaʻa laser ablative e hoʻoikaika i ka hoʻōla ʻana i ka ʻeha a hoʻihoʻi i ka hana pale ʻili.

2. Melasma a me ka Hyperpigmentation Post-inflammatory:

ʻO nā kumu maʻamau o ka melasma a me ka hyperpigmentation post-inflammatory ka nui o ka hoʻoulu ʻana o nā melanocytes a me nā pane inflammatory mau. Hiki i ka PDRN ke hoʻoponopono i nā ala kinase a me ka protein kinase B ma o ka hoʻoulu ʻana i ka hōʻailona extracellular i nā melanocytes, e hoʻohaʻahaʻa i nā pae o ka dysplastic angiotensin-related transcription factors, inhibiting the expression of tyrosinase and melanin synthesis-related proteins, a hōʻemi i ka melanin content o nā melanocytes. Ma ke kauka, hiki ke noʻonoʻo ʻia ka PDRN me nā ʻano hana ʻē aʻe e mālama ai i nā maʻi pigmentary refractory e like me ka melasma a i ʻole ka hyperpigmentation post-inflammatory. 3. ʻEleʻele ʻili:

Hoʻoulu ʻo PDRN i nā mea loaʻa adenosine A2A a i ʻole nā ala hoʻopakele, hoʻoponopono i ka cyclic adenosine monophosphate (cAMP) kaila, pale i ka MMPs a me ka huna elastase, hoʻoponopono hou i ka matrix extracellular, hoʻemi i nā wrinkles, hoʻihoʻi i ka elasticity ʻili, a hoʻomaikaʻi i ke ʻano o ka ʻili. Eia kekahi, ua ʻike nā haʻawina he nui e hiki i ka PDRN ke hoʻohaʻahaʻa i nā pae o nā mea pro-inflammatory like ʻole e like me IL-6, IL-1β, TNF-α, a me IL-12, a me ka hoʻoponopono ʻana i ka huna ʻana o nā mea inflammatory e like me IL-10. Hōʻike kēia e hiki i ka PDRN ke hoʻopaneʻe i ka hiki ʻana a me ka hoʻomohala ʻana o ka ʻili kiʻi ma o ke kāohi ʻana i ka huna ʻana o SASP, hoʻomaikaʻi i ka elasticity o ka ʻili, ka ʻeleʻele, a me ka nui o nā pores, a me ka hōʻemi ʻana i ka wai transepidermal, no laila e hoʻoponopono ai i nā pilikia ʻelemakule.

4. Kaʻili ʻili:

I loko o ka SD rat incision healing model, ua ʻike ʻia ʻo PDRN e hōʻemi i ka infiltration cell inflammatory i loko o ka ʻiʻo ʻili a keʻakeʻa i ka hoʻonui nui ʻana o ka ʻili ma ke kāohi ʻana i ka ʻōlelo HMGB-1. Ua ʻike nā haʻawina hauʻoli honua ʻo ka hoʻohana mua ʻana i ka PDRN ma hope o ka thyroidectomy hiki ke hoʻomaikaʻi nui i ke ʻano, ka waihoʻoluʻu, a me ka nui o nā ʻōpala hypertrophic, me ka palekana maikaʻi a ʻaʻohe hopena ʻino. No laila, hiki ke noʻonoʻo ʻia ka hana mua me ka PDRN no nā ʻeha i hiki ke loaʻa i ka scarring. I kēia manawa, ʻaʻohe haʻawina e pili ana i ka maikaʻi o ka PDRN i nā keloids.

5. Androgenetic Alopecia:

ʻO nā maʻi me ka androgenetic alopecia e hōʻike ana i nā loli o ke poʻo e like me ka hoʻemi ʻana a me ka liʻiliʻi o nā kīʻaha koko. Hiki i ka PDRN ke hoʻoponopono i ke ala hōʻailona Wnt, hoʻoikaika i ka ulu ʻana o ka lauoho lauoho, a hoʻonui i ka VEGF a me nā mea vasoactive ʻē aʻe, e hoʻomaikaʻi ai i ka androgenetic alopecia. Ua ʻike ʻia nā haʻawina prospective no nā poʻe maʻi me ka androgenetic alopecia i pane ʻole i ka lāʻau lapaʻau maʻamau, ʻo ka hoʻohana ʻana i ka PDRN i hui pū ʻia me ka PRP a i ʻole 1927nm thulium fractional laser lapaʻau hiki ke koho. Eia nō naʻe, ʻoi aku ka nui o ka laʻana e pono ai e loiloi i ka palekana.

6. Nā maʻi ʻili ʻē aʻe:

ʻO nā maʻi me ka androgenetic alopecia e hōʻike ana i nā loli o ke poʻo e like me ka hoʻemi ʻana a me ka liʻiliʻi o nā kīʻaha koko. Hiki i ka PDRN ke hoʻoponopono i ke ala hōʻailona Wnt, hoʻoikaika i ka ulu ʻana o ka lauoho lauoho, a hoʻonui i ka VEGF a me nā mea vasoactive ʻē aʻe, e hoʻomaikaʻi ai i ka androgenetic alopecia. Ua manaʻo ʻia nā haʻawina e hiki mai ana i kēia manawa ʻo PDRN i hui pū ʻia me ka PRP a i ʻole 1927nm thulium fractional laser lapaʻau hiki ke koho i nā mea maʻi me ka androgenetic alopecia i pane ʻole i ka lāʻau lapaʻau maʻamau. Eia nō naʻe, ʻoi aku ka nui o ka laʻana e pono ai e loiloi i kona palekana.

Hoʻohana ʻia

He ʻokoʻa ka hoʻohana ʻana i ka PDRN ma waena o nā maʻi like ʻole, a ʻaʻole naʻe ka protocol noi hui.

I kēia manawa, hōʻike nā palapala kūloko a me ka honua i nā ʻano hoʻokele PDRN me ka noi topical, intradermal delivery, intradermal injection, subcutaneous injection, a intramuscular injection. Hoʻokahi ka lōʻihi o ka hoʻopaʻa ʻana mai hoʻokahi lā a i hoʻokahi pule, a ʻo ka lōʻihi o ka hoʻohana ʻana mai kekahi mau lā a i kekahi mau pule. Eia nō naʻe, pono e hahai pono ʻia nā ʻano hoʻohana kikoʻī e like me ka hoʻohālikelike ʻana o ka huahana (lāʻau lapaʻau a i ʻole nā ​​​​mea lapaʻau).

Palekana a me ka mālama ʻana

1. Loaʻa i ka PDRN kahi maʻemaʻe DNA> 95% a ʻaʻole i loko o nā protein pharmacologically active a i ʻole peptides, no laila he haʻahaʻa kona immunogenicity.
2. Ua hōʻoia pū kekahi mau noiʻi lapaʻau he palekana maikaʻi a me ka hoʻomanawanui ʻana o PDRN me ka nānā ʻole i ke ala hoʻokele. ʻAʻole ʻike ʻia nā hopena ʻona nui a i ʻole nā ​​hopena koʻikoʻi koʻikoʻi ma hope o ka hoʻohana ʻana i ke kumuhana, ʻoiai e hiki mai ana nā hopena ʻino e like me ka ʻulaʻula o ka ʻili, ka ʻili, a me ke kuʻi. E emi koke ana kēia mau hōʻailona ma hope o ka pau ʻana o ka lāʻau lapaʻau a i ʻole me ka mālama ʻana i nā hōʻailona.
3. Loaʻa ka hiki ke loaʻa nā hanana ʻino e like me ka granulomas kino haole a me nā maʻi kikoʻī i ka wā e lawelawe ʻia ai ka PDRN e ka injection. No laila, pono e mālama ʻia i ka wā e hoʻohana ai i kēia lāʻau lapaʻau intradermally a i ʻole subcutaneously.
4. Hoʻopaʻa ʻia ka PDRN i nā wahine hāpai a me ka lactating, ka poʻe me nā ʻeha maʻi, a me nā mea maʻi i ka PDRN.

Hōʻuluʻulu manaʻo a me Outlook

1. Ma Kina, hoʻohana nui ʻia ka PDRN ma luna o ka microneedling mesotherapy. Hāʻawi ʻia i nā hopena anti-inflammatory o PDRN a me nā hiki ke hoʻomaikaʻi hou i ka ʻiʻo, hiki i ka noiʻi e hiki mai ana ke ʻimi i kona hiki no nā noi hou.
2. Eia kekahi, ʻo nā hoʻolālā hoʻokele no ka PDRN i ka mālama ʻana i nā pilikia ʻili like ʻole, me ka hoʻoholo ʻana i ke ala kūpono o ka hoʻokele, ka pinepine, a me ka noʻonoʻo ʻana, a me kāna mau hopena synergistic me nā lāʻau lapaʻau ʻē aʻe, pono e noiʻi hou aku.